Bruno Caramelli, Pai Ching Yu, Francisco A M Cardozo, Iuri R Magalhães, Raphael R Spera, Daniel K Amado, Maria C Escalante-Rojas, Danielle M Gualandro, Daniela Calderaro, Caio A M Tavares, Flavio A Borges-Junior, Adriana F Pastana, Mariana G Matheus, Sonia M D Brucki, Ana Carolina O Rodrigues, Ricardo Nitrini, Paulo Caramelli
BACKGROUND: Observational studies support a role for oral anticoagulation to reduce the risk of dementia in atrial fibrillation patients, but conclusive data are lacking. Since dabigatran offers a more stable anticoagulation, we hypothesized it would reduce cognitive decline when compared to warfarin in old patients with atrial fibrillation. METHODS: The GIRAF trial was a 24-month, randomized, parallel-group, controlled, open-label, hypothesis generating trial. The trial was done in six centers including a geriatric care unit, secondary and tertiary care cardiology hospitals in São Paulo, Brazil...
October 26, 2022: BMC Medicine